Show simple item record

dc.contributor.authorBowyer, Sen_US
dc.contributor.authorPrithviraj, Pen_US
dc.contributor.authorLorigan, Pen_US
dc.contributor.authorLarkin, Jen_US
dc.contributor.authorMcArthur, Gen_US
dc.contributor.authorAtkinson, Ven_US
dc.contributor.authorMillward, Men_US
dc.contributor.authorKhou, Men_US
dc.contributor.authorDiem, Sen_US
dc.contributor.authorRamanujam, Sen_US
dc.contributor.authorKong, Ben_US
dc.contributor.authorLiniker, Een_US
dc.contributor.authorGuminski, Aen_US
dc.contributor.authorParente, Pen_US
dc.contributor.authorAndrews, MCen_US
dc.contributor.authorParakh, Sen_US
dc.contributor.authorCebon, Jen_US
dc.contributor.authorLong, GVen_US
dc.contributor.authorCarlino, MSen_US
dc.contributor.authorKlein, Oen_US
dc.date.accessioned2017-03-24T15:36:20Z
dc.date.issued2016-05en_US
dc.identifier.citationBritish journal of cancer, 2016, 114 (10), pp. 1084 - 1089en_US
dc.identifier.issn0007-0920en_US
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/528
dc.identifier.eissn1532-1827en_US
dc.identifier.doi10.1038/bjc.2016.107en_US
dc.description.abstract<h4>Background</h4>Recent phase III clinical trials have established the superiority of the anti-PD-1 antibodies pembrolizumab and nivolumab over the anti-CTLA-4 antibody ipilimumab in the first-line treatment of patients with advanced melanoma. Ipilimumab will be considered for second-line treatment after the failure of anti-PD-1 therapy.<h4>Methods</h4>We retrospectively identified a cohort of 40 patients with metastatic melanoma who received single-agent anti-PD-1 therapy with pembrolizumab or nivolumab and were treated on progression with ipilimumab at a dose of 3 mg kg(-1) for a maximum of four doses.<h4>Results</h4>Ten percent of patients achieved an objective response to ipilimumab, and an additional 8% experienced prolonged (>6 months) stable disease. Thirty-five percent of patients developed grade 3-5 immune-related toxicity associated with ipilimumab therapy. The most common high-grade immune-related toxicity was diarrhoea. Three patients (7%) developed grade 3-5 pneumonitis leading to death in one patient.<h4>Conclusions</h4>Ipilimumab therapy can induce responses in patients who fail the anti-PD-1 therapy with response rates comparable to previous reports. There appears to be an increased frequency of high-grade immune-related adverse events including pneumonitis that warrants close surveillance.en_US
dc.formatPrint-Electronicen_US
dc.format.extent1084 - 1089en_US
dc.languageengen_US
dc.language.isoengen_US
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/en_US
dc.subjectHumansen_US
dc.subjectMelanomaen_US
dc.subjectSkin Neoplasmsen_US
dc.subjectNeoplasm Metastasisen_US
dc.subjectAntineoplastic Agentsen_US
dc.subjectAntibodies, Monoclonalen_US
dc.subjectTreatment Outcomeen_US
dc.subjectDrug Administration Scheduleen_US
dc.subjectRetrospective Studiesen_US
dc.subjectAdulten_US
dc.subjectAgeden_US
dc.subjectMiddle Ageden_US
dc.subjectFemaleen_US
dc.subjectMaleen_US
dc.subjectIpilimumaben_US
dc.titleEfficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy.en_US
dc.typeJournal Article
dcterms.dateAccepted2016-03-14en_US
rioxxterms.versionofrecord10.1038/bjc.2016.107en_US
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by-nc-sa/4.0en_US
rioxxterms.licenseref.startdate2016-05en_US
rioxxterms.typeJournal Article/Reviewen_US
dc.relation.isPartOfBritish journal of canceren_US
pubs.issue10en_US
pubs.notes12 monthsen_US
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Melanoma and Kidney Cancer
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Melanoma and Kidney Cancer/Melanoma and Kidney Cancer (hon.)
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublisheden_US
pubs.volume114en_US
pubs.embargo.terms12 monthsen_US
icr.researchteamMelanoma and Kidney Canceren_US
dc.contributor.icrauthorLarkin, Jamesen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

http://creativecommons.org/licenses/by/4.0/
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by/4.0/